# name
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)

# metadata.dc.description.abstract[].value
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for patients with newly diagnosed GB up to age 70. Recently, a new standard of care has been adopted for elderly patients (65 years) based on short course of RT and TMZ. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors. The presence of neurologic deficits and seizures can significantly impact quality of life.

# metadata.dc.relation.ispartof[].value
Clinical & Translational Oncology, 2018-01-01, Vol. 20, Issue 1, P. 22-28

# metadata.dc.rights[].value
cc by (c) Martínez García, M., et al., 2018

# metadata.dc.source[].value
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

# metadata.dc.title[].value
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)